{"entity":{"id":"nct05714839","kind":"trial","name":"A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme","aka":["DynaMMic-1"],"tldr":"A phase 1/2 trial of Belantamab mafodotin, Pomalidomide, Dexamethasone in multiple myeloma, run by GlaxoSmithKline, now recruiting.","summary":"A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments is a phase 1/2 interventional study registered as NCT05714839 by GlaxoSmithKline, with 123 participants planned, started 2023-06-14 and due to reach its primary completion in 2028-08-03. Interventions recorded: Belantamab, Belantamab mafodotin, Pomalidomide, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05714839","url":"https://clinicaltrials.gov/study/NCT05714839"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["belantamab-mafodotin","pomalidomide","dexamethasone"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05714839","phase":"1/2","setting":"A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple Myeloma","sponsor":"GlaxoSmithKline","participation":[{"nct":"NCT05714839","source":"https://clinicaltrials.gov/study/NCT05714839","fetchedAt":"2026-10-07T16:53:52.193Z","studySha256":"2c963e1c3bdfbe61e5ac585723ec38d17998967ceb0ca99cd879732585415c3f","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-19","leadSponsor":"GlaxoSmithKline","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":123,"enrolmentType":"ESTIMATED","siteCount":44,"recruitingSiteCount":39,"countries":["Argentina","Australia","Brazil","China","Israel","Japan","Poland","South Africa","South Korea","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2023-06-14","startedType":"actual","enrolled":123,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05714839/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/"},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"pomalidomide","kind":"drug","name":"Pomalidomide","route":"/drugs/pomalidomide/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}